Navigation Links
Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
Date:6/1/2011

GENEVA, June 1, 2011 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company with technologies for the rapid development and engineering of high yield and stable mammalian cell lines for therapeutic protein manufacturing of recombinant drugs announced today representatives from the Company will be participating in the 2011 BIO International Convention's One-on-One Partnering Meetings being held Jun 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.

Selexis has interactive collaborations, partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. Selexis' SURE technology platform allows for faster and more reliable cell line development with higher expression levels which can be applied to a wide range of areas such as bio-manufacturing, drug discovery, diagnostics and therapeutics.

Representatives available to discuss Selexis' capabilities include: Dr. Igor Fisch, CEO; Andrew Sandford, VP Business Development and Licensing; Dr. Armelle Gaussin, Chief Technology Officer; and Dr. Denise Huber, Director of Business Development. Companies or individuals attending BIO 2011 can schedule meetings with Selexis by visiting (registration required): oneononepartnering.bio.org/BusinessForum2011/Login.aspx.

Selexis Partnering Schedule:

Monday, June 27 Business Forum  -  12:00 PM - 5:00 PM

Tuesday, June 28 Business Forum  -  7:00 AM – 6:00 PM

Wednesday, June 29 Business Forum  -  7:00 AM – 6:00 PM

Thursday, June 30 Business Forum  -  7:00 AM – 6:00 PM

For companies or individuals not participating in partnering meetings, Selexis will be exhibiting in booth number #1906 located in Hall A – Discovery Zone (e.mybio.zerista.com/exhibitor/member/17326). For the exhibit hall schedule, visit: e.mybio.zerista.com/event/print

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SUREvariant Screening™ and the proprietary Selexis SURE CHO-M Cell Line™.

For more information visit www.selexis.com

Contact:
Robert Meister
(602) 953-1716
robert.meister@selexis.com


'/>"/>
SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
2. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
3. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
4. Selexis Launches Biosimilar Cell Line Development Program
5. Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development
6. Local Partnership Addresses Lagging Scores and Interest in Science and Math Among Students
7. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
8. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
9. Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research
10. Aperio Partners with Definiens to Market Definiens Tissue Studio for Advanced Image Analysis
11. John McKearn, Ph.D., Promoted to Managing Director of RiverVest Venture Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... quality, regulatory and technical consulting, provides a free webinar on Performing ... July 13, 2016 at 12pm CT at no charge. , Incomplete investigations are ...
(Date:6/23/2016)... ReportsnReports.com adds 2016 global ... pharmaceuticals section with historic and forecast data along ... Complete report on the Cell Culture ... companies and supported with 261 tables and figures ... The Global Cell Culture Media Industry ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):